BACKGROUND: Currently, tumor-node-metastasis stage and histologic type are the established prognostic factors for malignant pleural mesothelioma, whereas no prognostic markers have been established for clinical practice. We investigated the prognostic value of CD10, a metalloproteinase that can promote cancer aggressiveness through enzymatic degradation and intracellular signaling crosstalk, in malignant pleural mesothelioma. METHODS: CD10 immunostaining was performed for 176 cases of malignant pleural mesothelioma (epithelioid, 148; biphasic, 14; sarcomatoid, 14), and its expression was dichotomized as negative (no staining) or positive (any staining). Epithelioid tumors were classified as pleomorphic subtype when cytologic pleomorphism was ≥10 % of the tumor. Overall survival (OS) was analyzed by log-rank tests and Cox proportional hazard models. RESULTS: Tumoral CD10 expression was identified in 42 % of epithelioid non-pleomorphic tumors, 57 % of epithelioid pleomorphic tumors, 79 % of biphasic tumors, and 93 % of sarcomatoid tumors (p < 0.001). Positive CD10 expression was correlated with higher mitotic count (p = 0.002). Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression in all patients (p = 0.001) and in patients with epithelioid tumor (p = 0.04). On multivariate analysis, CD10 expression was an independent prognostic factor for all patients (hazard ratio 1.48; p = 0.019). CONCLUSIONS: Tumoral CD10 expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for patients with malignant pleural mesothelioma.
BACKGROUND: Currently, tumor-node-metastasis stage and histologic type are the established prognostic factors for malignant pleural mesothelioma, whereas no prognostic markers have been established for clinical practice. We investigated the prognostic value of CD10, a metalloproteinase that can promote cancer aggressiveness through enzymatic degradation and intracellular signaling crosstalk, in malignant pleural mesothelioma. METHODS:CD10 immunostaining was performed for 176 cases of malignant pleural mesothelioma (epithelioid, 148; biphasic, 14; sarcomatoid, 14), and its expression was dichotomized as negative (no staining) or positive (any staining). Epithelioid tumors were classified as pleomorphic subtype when cytologic pleomorphism was ≥10 % of the tumor. Overall survival (OS) was analyzed by log-rank tests and Cox proportional hazard models. RESULTS:TumoralCD10 expression was identified in 42 % of epithelioid non-pleomorphic tumors, 57 % of epithelioid pleomorphic tumors, 79 % of biphasic tumors, and 93 % of sarcomatoid tumors (p < 0.001). Positive CD10 expression was correlated with higher mitotic count (p = 0.002). Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression in all patients (p = 0.001) and in patients with epithelioid tumor (p = 0.04). On multivariate analysis, CD10 expression was an independent prognostic factor for all patients (hazard ratio 1.48; p = 0.019). CONCLUSIONS:TumoralCD10 expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for patients with malignant pleural mesothelioma.
Authors: Kelly J Butnor; Andrew G Nicholson; D Craig Allred; Dani S Zander; Douglas W Henderson; Roberto Barrios; Abida K Haque; Timothy C Allen; Deanna E Killen; Philip T Cagle Journal: Arch Pathol Lab Med Date: 2006-06 Impact factor: 5.534
Authors: Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis Journal: Mod Pathol Date: 2012-04-13 Impact factor: 7.842
Authors: Valerie W Rusch; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Harvey Pass; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck Journal: J Thorac Oncol Date: 2012-11 Impact factor: 15.609
Authors: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Kei Suzuki; Kyuichi Kadota; Camelia S Sima; Jun-ichi Nitadori; Valerie W Rusch; William D Travis; Michel Sadelain; Prasad S Adusumilli Journal: J Clin Oncol Date: 2012-12-26 Impact factor: 44.544
Authors: Marc A Dall'Era; Lawrence D True; Andrew F Siegel; Michael P Porter; Tracy M Sherertz; Alvin Y Liu Journal: BMC Urol Date: 2007-03-02 Impact factor: 2.264
Authors: Melissa E Ho; Sue-Ing Quek; Lawrence D True; Colm Morrissey; Eva Corey; Robert L Vessella; Ruth Dumpit; Peter S Nelson; Erin L Maresh; Vei Mah; Mohammed Alavi; Sara R Kim; Lora Bagryanova; Steve Horvath; David Chia; Lee Goodglick; Alvin Y Liu Journal: Mod Pathol Date: 2013-01-25 Impact factor: 7.842
Authors: T Fukusumi; H Ishii; M Konno; T Yasui; S Nakahara; Y Takenaka; Y Yamamoto; S Nishikawa; Y Kano; H Ogawa; S Hasegawa; A Hamabe; N Haraguchi; Y Doki; M Mori; H Inohara Journal: Br J Cancer Date: 2014-05-29 Impact factor: 7.640
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Hideki Ujiie; Daniel H Buitrago; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Kyuichi Kadota; Daniel Buitrago; Ming-Ching Lee; Jonathan Villena-Vargas; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli Journal: Lung Cancer Date: 2015-06-15 Impact factor: 5.705